Com parative study on application of ambroxol and dexamethasone in patients with gestational diabetes prevention of neonatal respiratory distress syndrome
LIU Qing LAIHai-li LIU Gui-rong KE Ying
Maternal and Child Health Care Hospital of Ganzhou City in Jiangxi Province，Ganzhou 341000，China
Abstract：Objective To explore clinical effects of application of ambroxol and dexamethasone in patients with gestational diabetes prevention of neonatal respiratory distress syndrome. Methods Gestational diabetes complicated with premature labor（150 cases）treated in our hospital from January 2014 to July 2015 were randomly divided into 3 groups and given ambroxol intravenous injection （mucosolvan treatment group 50 cases），dexamethasone intravenous injection （dexamethasone treatment group 50 cases）and no treatment（control group 50 cases），incidence of patientswith premature neonatal with respiratory distress syndrome among three groups was compared，intrauterine infection rate，neonatal infection rates，elevated maternal blood glucose and other indicators of patients in three groupswere counted.Results Incidence rate of premature infants with neonatal respiratory distress syndrome was 3.3%in ambroxol treatment group，with 10.0%in dexamethasone treatment group，with 24.0%in control group，the incidence of premature infants with neonatal respiratory distress syndrome in ambroxol treatment group lower less than that in dexamethasone treatment group，and the incidence in dexamethasone treatment group was lower than that in the control group，the difference both were significant（P＜0.05）.The rate of intrauterine infection and neonatal infection rate in ambroxol treatment group were lower than those in dexamethasone treatment group，with significant difference （P＜0.05）；at the same time，the rate of intrauterine infection and neonatal infection rate in dexamethasone treatment group were less than those in control group，and the difference was significant（P＜0.05）.Ambroxol treatment group compared with control group，after medication fasting blood glucose level and postprandial 2 h blood glucose level had no significant difference （P＞0.05），and dexamethasone treatment group compared with control group，aftermedication postprandial 2 h blood glucose levelwas significantly elevated，the difference was significant（P＜0.05）.Conclusion Ambroxol can effectively reduce incidence of gestational diabetes patientswith neonatal respiratory distress syndrome，and reducematernal intrauterine infection rate and neonatal infection rate，blood glucose level has not been affected，which isworthy of clinical promotion.
刘青 ；赖海丽； 刘桂荣 ；柯莹. 妊娠期糖尿病患者应用沐舒坦和地塞米松预防新生儿呼吸窘迫综合征的对比研究[J]. 中国当代医药, 2016, 23(23): 75-77.
LIU Qing； LAIHai-li ；LIU Gui-rong； KE Ying. Com parative study on application of ambroxol and dexamethasone in patients with gestational diabetes prevention of neonatal respiratory distress syndrome. 中国当代医药, 2016, 23(23): 75-77.
京公网安备 11010502046607号